HC Wainwright Has Optimistic View of GH Research Q1 Earnings

GH Research PLC (NASDAQ:GHRS) – Equities researchers at HC Wainwright upped their Q1 2025 earnings estimates for shares of GH Research in a report issued on Tuesday, March 4th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.19) for the quarter, up from their previous estimate of ($0.22). HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for GH Research’s Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($0.82) EPS, FY2026 earnings at ($0.88) EPS, FY2027 earnings at ($0.92) EPS and FY2028 earnings at ($0.46) EPS.

A number of other research firms also recently issued reports on GHRS. Cantor Fitzgerald started coverage on shares of GH Research in a report on Thursday, February 13th. They set an “overweight” rating and a $14.00 price objective on the stock. Canaccord Genuity Group cut their price objective on shares of GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a report on Monday, November 18th. Finally, Stifel Nicolaus lifted their price objective on shares of GH Research from $18.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, GH Research currently has an average rating of “Buy” and an average target price of $30.60.

GH Research Price Performance

GHRS opened at $10.55 on Friday. The company has a market capitalization of $548.90 million, a price-to-earnings ratio of -13.35 and a beta of 0.94. The firm’s fifty day moving average price is $10.73 and its two-hundred day moving average price is $9.20. GH Research has a 1 year low of $6.00 and a 1 year high of $20.50.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06.

Institutional Investors Weigh In On GH Research

A number of hedge funds have recently made changes to their positions in GHRS. RA Capital Management L.P. raised its stake in shares of GH Research by 1.3% during the 3rd quarter. RA Capital Management L.P. now owns 6,686,689 shares of the company’s stock worth $44,734,000 after purchasing an additional 85,000 shares during the period. Geode Capital Management LLC raised its stake in shares of GH Research by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 72,513 shares of the company’s stock worth $508,000 after purchasing an additional 3,092 shares during the period. Diadema Partners LP bought a new stake in shares of GH Research during the 4th quarter worth $711,000. Lynx1 Capital Management LP raised its stake in shares of GH Research by 15.8% during the 4th quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company’s stock worth $34,013,000 after purchasing an additional 663,100 shares during the period. Finally, Northern Trust Corp raised its stake in shares of GH Research by 26.8% during the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock worth $286,000 after purchasing an additional 8,641 shares during the period. 56.90% of the stock is currently owned by institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).